Human haptoglobin quantikine elisa kit

In the validation phase, we used a separate cohort of 72 volunteers (MM = 36, control = 36) to perform ELISA based validation in serum samples. All the ELISA experiments were performed according to the manufacturer’s instructions. We validated a panel of five proteins with the Human Haptoglobin Quantikine ELISA kit (catalog #DHAPG0; R&D Systems, Inc., Minneapolis, USA), Human Kininogen DuoSet ELISA kit (catalog #DY1569-05; R&D Systems, Inc., Minneapolis, USA), Human Apolipoprotein A-I Quantikine ELISA Kit (catalog #DAPA10; R&D Systems, Inc., Minneapolis, USA), Human sTfR Quantikine IVD ELISA Kit (1 Kit) (catalog #DTFR1; R&D Systems, Inc., Minneapolis, USA), Human Serum Albumin DuoSet ELISA, 15 Plate (1 KIT) (catalog #DY1455; R&D Systems, Inc., Minneapolis, USA). The optical density of the each sample was determined by using an EPOCH 2 microplate reader (Biotek, USA) set to 450 nm and 570 nm. Optical imperfections correction was done by subtracting the readings of 570 nm from 450 nm readings. Further quantitative analysis was performed using GraphPad Prism software.

An enzyme-linked immunosorbent assay (ELISA) was used to measure Hp concentrations by using a Human Haptoglobin Quantikine ELISA kit (R&D Systems, Inc., Minneapolis, USA) following the kit manufacturer’s instructions as described previously [12 (link)].

Serum samples were collected from 50 patients with prostate cancer and bone metastasis, 50 patients with prostate cancer without metastasis and 50 patients with benign prostatic hyperplasia. The Human CD 59 ELISA Kit (Ray Biotech , Norcross, USA), Human Haptoglobin Quantikine ELISA Kit (R&D, Minneapolis, USA), and Custom Human CLEC3B ELISA Kit (Ray Biotech, Norcross, USA) were used to detect the levels of CD59, haptoglobin and tetranectin, respectively. All operations were carried out in strict accordance with the manufacturer's operation manual.